| # | Code | QID |
Subspecialty
|
Topic
|
Complexity
|
Importance
|
Question Count |
|---|---|---|---|---|---|---|---|
| 1 | M1.OMB.20.1 | 213740 | Ethical Principles |
L3
|
A
|
0
0%
0
|
|
| 2 | M1.OMB.20.4770 | 214203 | Legal Principles |
L1
|
A
|
0
0%
0
|
|
| 3 | M1.OMB.20.4730 | 213799 | Testing and Screening |
A
|
0
0%
0
|
||
| 4 | M1.OMB.20.1 | 213780 | Lysosome |
L2
|
A
|
0
0%
0
|
|
| 5 | M1.OMB.20.1 | 214271 | Lysosome |
L2
|
A
|
0
0%
0
|
|
| 6 | M1.OMB.20.4874 | 213726 | Primary Brain Tumors |
L2
|
A
|
0
0%
0
|
|
| 7 | M1.OMB.20.1 | 214278 | Primary Brain Tumors |
L2
|
A
|
0
0%
0
|
|
| 8 | M1.OMB.20.4875 | 213879 | Modes of Inheritance |
L1
|
A
|
0
0%
0
|
|
| 9 | M1.OMB.20.4875 | 214229 | Congestive Heart Failure |
L2
|
A
|
0
0%
0
|
|
| 10 | M1.OMB.20.1 | 213781 | Congestive Heart Failure |
L3
|
A
|
0
0%
0
|
|
| 11 | M1.OMB.20.1 | 214193 | Statistical Measures |
L1
|
A
|
0
0%
0
|
|
| 12 | M1.OMB.20.4767 | 214302 | Statistical Measures |
L1
|
A
|
0
0%
0
|
|
| 13 | M1.OMB.20.1 | 214276 | Cranial Nerves |
L2
|
A
|
0
0%
0
|
|
| 14 | M1.OMB.20.1 | 213768 | Graves Disease |
L2
|
A
|
0
0%
0
|
|
| 15 | M1.OMB.20.1 | 214275 | Valvular Disease |
L2
|
A
|
0
0%
0
|
|
| 16 | M1.OMB.20.4758 | 214220 | Urinary Tract Infection |
L3
|
A
|
0
0%
0
|
|
| 17 | M1.OMB.20.4801 | 213892 | Other Eating Disorders |
L4
|
A
|
0
0%
0
|
|
| 18 | M1.OMB.20.1 | 214273 | Fat Soluble Vitamins |
L2
|
A
|
0
0%
0
|
|
| 19 | M1.OMB.20.4801 | 214223 | HIV |
L2
|
A
|
0
0%
0
|
|
| 20 | M1.OMB.20.138 | 213869 | Emphysema |
L2
|
A
|
0
0%
0
|
|
| 21 | M1.OMB.20.1 | 213779 | Opiates |
L3
|
A
|
0
0%
0
|
|
| 22 | M1.OMB.20.1 | 213883 | Opiates |
L1
|
A
|
0
0%
0
|
|
| 23 | M1.OMB.20.1 | 213887 | Amino Acid Catabolism |
L1
|
A
|
0
0%
0
|
|
| 24 | M1.OMB.20.4802 | 214288 | Germ Layer Derivatives |
L2
|
A
|
0
0%
0
|
|
| 25 | M1.OMB.20.1 | 214180 | Anticoagulants |
L3
|
A
|
0
0%
0
|
|
| 26 | M1.OMB.20.4818 | 213846 | Diabetic Ketoacidosis (DKA) |
L2
|
A
|
0
0%
0
|
|
| 27 | M1.OMB.20.4870 | 213722 | Somatic Symptom and Related Disorders |
L2
|
A
|
0
0%
0
|
|
| 28 | M1.OMB.20.4870 | 213798 | Nephrolithiasis |
L2
|
A
|
0
0%
0
|
|
| 29 | M1.OMB.20.4767 | 213839 | Baroreceptors and Chemoreceptors |
L1
|
A
|
0
0%
0
|
|
| 30 | M1.OMB.20.4885 | 213806 | Abdominal Aortic Aneurysm |
L4
|
A
|
0
0%
0
|
|
| 31 | M1.OMB.20.1 | 214199 | Baroreceptors and Chemoreceptors |
L1
|
A
|
0
0%
0
|
|
| 32 | M1.OMB.20.1 | 213854 | Cardiomyopathies |
L2
|
A
|
0
0%
0
|
|
| 33 | M1.OMB.20.1 | 213787 | Immunosuppressive Drugs |
L3
|
A
|
0
0%
0
|
|
| 34 | M1.OMB.20.1 | 213782 | Streptococcus pneumoniae |
L3
|
A
|
0
0%
0
|
|
| 35 | M1.OMB.20.4662 | 213860 | Population Genetics |
L1
|
A
|
0
0%
0
|
|
| 36 | M1.OMB.20.1 | 213882 | Atrioventricular (AV) Heart Block |
L2
|
A
|
0
0%
0
|
|
| 37 | M1.OMB.20.1 | 214260 | Klinefelter Syndrome |
L2
|
A
|
0
0%
0
|
|
| 38 | M1.OMB.20.1 | 213714 | Acute Interstitial Nephritis |
L3
|
A
|
0
0%
0
|
|
| 39 | M1.OMB.20.4754 | 214200 | Antianginal Therapy |
L3
|
A
|
0
0%
0
|
|
| 40 | M1.OMB.20.1 | 214279 | Obsessive-Compulsive Disorder |
L3
|
A
|
0
0%
0
|
|
| 41 | M1.OMB.20.1 | 213868 | Complement |
L2
|
A
|
0
0%
0
|
|
| 42 | M1.OMB.20.4886 | 214299 | Pneumoconioses |
L2
|
A
|
0
0%
0
|
|
| 43 | M1.OMB.20.4697 | 213792 | Gastrointestinal Tract Histology |
L2
|
A
|
0
0%
0
|
|
| 44 | M1.OMB.20.4868 | 213891 | Bruton Agammaglobulinemia |
L2
|
A
|
0
0%
0
|
|
| 45 | M1.OMB.20.1 | 213716 | Loop Diuretics |
L3
|
A
|
0
0%
0
|
|
| 46 | M1.OMB.20.1 | 213785 | K-Sparing Diuretics |
L3
|
A
|
0
0%
0
|
|
| 47 | M1.OMB.20.1 | 213770 | Psoriasis |
L2
|
A
|
0
0%
0
|
|
| 48 | M1.OMB.20.2 | 213807 | Interventional Studies |
L1
|
A
|
0
0%
0
|
|
| 49 | M1.OMB.20.4800 | 213871 | Parkinson Disease |
L2
|
A
|
0
0%
0
|
|
| 50 | M1.OMB.20.1 | 214197 | Benign Prostatic Hyperplasia (BPH) |
L3
|
A
|
0
0%
0
|
|
| 51 | M1.OMB.20.1 | 214196 | Acute Kidney Injury |
L2
|
A
|
0
0%
0
|
|
| 52 | M1.OMB.20.4885 | 213739 | Renal Cyst Disorders |
L2
|
A
|
0
0%
0
|
|
| 53 | M1.OMB.20.1 | 213876 | Hepatic Encephalopathy |
L2
|
A
|
0
0%
0
|
|
| 54 | M1.OMB.20.4673 | 214219 | Chronic Kidney Disease (CKD) |
L2
|
A
|
0
0%
0
|
|
| 55 | M1.OMB.20.4698 | 213810 | Visceral Infections: Protozoa |
L2
|
A
|
0
0%
0
|
|
| 56 | M1.OMB.20.1 | 213783 | Dosage Calculations |
L1
|
A
|
0
0%
0
|
|
| 57 | M1.OMB.20.1 | 213877 | Hepatic Encephalopathy |
L3
|
A
|
0
0%
0
|
|
| 58 | M1.OMB.20.4870 | 213757 | Staphylococcus aureus |
L2
|
A
|
0
0%
0
|
|
| 59 | M1.OMB.20.3 | 213858 | Brachial Plexus Lesions |
L2
|
A
|
0
0%
0
|
|
| 60 | M1.OMB.20.1 | 214179 | Stages of Development |
L2
|
A
|
0
0%
0
|
|
| 61 | M1.OMB.20.112405 | 213855 | Psychotherapy |
L2
|
A
|
0
0%
0
|
|
| 62 | M1.OMB.20.1 | 213718 | Lithium |
L3
|
A
|
0
0%
0
|
|
| 63 | M1.OMB.20.4756 | 214228 | Multiple Myeloma |
L2
|
A
|
0
0%
0
|
|
| 64 | M1.OMB.20.1 | 213850 | Tricyclic Antidepressants (TCAs) |
L3
|
A
|
0
0%
0
|
|
| 65 | M1.OMB.20.77 | 214295 | Amphotericin B |
L2
|
A
|
0
0%
0
|
|
| 66 | M1.OMB.20.1 | 214182 | Cardiac Glycosides (Digoxin) |
L3
|
A
|
0
0%
0
|
|
| 67 | M1.OMB.20.4868 | 213873 | Antimetabolites |
L3
|
A
|
0
0%
0
|
|
| 68 | M1.OMB.20.4801 | 214218 | Principles of Neoplasia |
L1
|
A
|
0
0%
0
|
|
| 69 | M1.OMB.20.1 | 213717 | G Protein-Coupled Receptors (GPCR) |
L1
|
A
|
0
0%
0
|
|
| 70 | M1.OMB.20.1 | 213888 | Systemic Lupus Erythematosus |
L2
|
A
|
0
0%
0
|
|
| 71 | M1.OMB.20.113 | 214216 | Hypercalcemia |
L2
|
A
|
0
0%
0
|
|
| 72 | M1.OMB.20.4800 | 214212 | Neurotransmitters |
L1
|
A
|
0
0%
0
|
|
| 73 | M1.OMB.20.4725 | 213725 | Lower Extremity Innervation |
L2
|
A
|
0
0%
0
|
|
| 74 | M1.OMB.20.4874 | 213808 | Electrolyte Disturbances |
L2
|
A
|
0
0%
0
|
|
| 75 | M1.OMB.20.1 | 213885 | Glucose Transport |
L1
|
A
|
0
0%
0
|
|
| 76 | M1.OMB.20.32 | 214282 | Cleft Lip and Palate |
L2
|
A
|
0
0%
0
|
|
| 77 | M1.OMB.20.4871 | 214281 | Thrombotic Thrombocytopenic Purpura (TTP) |
L2
|
A
|
0
0%
0
|
|
| 78 | M1.OMB.20.4726 | 214322 | Lower Extremity Innervation |
L2
|
A
|
0
0%
0
|
|
| 79 | M1.OMB.20.1 | 214274 | Epigenetics |
L2
|
A
|
0
0%
0
|
|
| 80 | M1.OMB.20.4875 | 213845 | Clostridium perfringens |
L2
|
A
|
0
0%
0
|
|
| 81 | M1.OMB.20.4870 | 213794 | Protein Folding and Degradation |
L2
|
A
|
0
0%
0
|
|
| 82 | M1.OMB.20.1 | 213767 | Bronchiectasis |
L2
|
A
|
0
0%
0
|
|
| 83 | M1.OMB.20.4874 | 213861 | H2 Blockers |
L3
|
A
|
0
0%
0
|
|
| 84 | M1.OMB.20.4709 | 213848 | Sjogren Syndrome |
L2
|
A
|
0
0%
0
|
|
| 85 | M1.OMB.20.4699 | 213719 | Immune Thrombocytopenia (ITP) |
A
|
0
0%
0
|
||
| 86 | M1.OMB.20.1 | 214181 | Intervertebral Disk Herniation |
L2
|
A
|
0
0%
0
|
|
| 87 | M1.OMB.20.63 | 213710 | Hyperlipidemia Signs |
L2
|
A
|
0
0%
0
|
|
| 88 | M1.OMB.20.4754 | 213874 | Growth Hormone Adenoma / Acromegaly |
L3
|
A
|
0
0%
0
|
|
| 89 | M1.OMB.20.4754 | 214303 | 5-Alpha Reductase Deficiency |
L2
|
A
|
0
0%
0
|
|
| 90 | M1.OMB.20.1 | 213784 | Pleural Effusion |
L2
|
A
|
0
0%
0
|
|
| 91 | M1.OMB.20.1 | 213769 | Syndrome of Inappropriate ADH (SIADH) |
L1
|
A
|
0
0%
0
|
|
| 92 | M1.OMB.20.1 | 214194 | Response to High Altitude |
L2
|
A
|
0
0%
0
|
|
| 93 | M1.OMB.20.4874 | 213878 | Malignant Breast Tumors |
L2
|
A
|
0
0%
0
|
|
| 94 | M1.OMB.20.2 | 214222 | Antiphospholipid Syndrome |
L2
|
A
|
0
0%
0
|
|
| 95 | M1.OMB.20.4754 | 213847 | Hashimoto Thyroiditis |
L2
|
A
|
0
0%
0
|
|
| 96 | M1.OMB.20.4698 | 214227 | Renin-Angiotensin-Aldosterone System |
L2
|
A
|
0
0%
0
|
|
| 97 | M1.OMB.20.184 | 214185 | Helicobacter pylori |
L2
|
A
|
0
0%
0
|
|
| 98 | M1.OMB.20.4870 | 213723 | Hydatidiform Mole |
L2
|
A
|
0
0%
0
|
|
| 99 | M1.OMB.20.4775 | 213841 | Immunization |
L1
|
A
|
0
0%
0
|
|
| 100 | M1.OMB.20.4721 | 214211 | Primary Biliary Cholangitis |
L2
|
A
|
0
0%
0
|
|
| 101 | M1.OMB.20.1 | 214198 | Therapeutic Index |
L1
|
A
|
0
0%
0
|
|
| 102 | M1.OMB.20.1 | 213881 | Reverse Transcription |
L1
|
A
|
0
0%
0
|
|
| 103 | M1.OMB.20.1 | 213890 | Polycystic Ovarian Syndrome |
L2
|
A
|
0
0%
0
|
|
| 104 | M1.OMB.20.6002 | 213844 | Yersinia enterocolitica |
L2
|
A
|
0
0%
0
|
|
| 105 | M1.ST.20.2 | 213857 | Neuronal Support Cells |
L1
|
A
|
0
0%
0
|
|
| 106 | M1.OMB.20.4799 | 213724 | Headache |
L3
|
A
|
0
0%
0
|
|
| 107 | M1.OMB.20.4720 | 213727 | Basal Cell Carcinoma of the Skin |
L2
|
A
|
0
0%
0
|
|
| 108 | M1.OMB.20.1 | 213884 | Blood Cell Types |
L1
|
A
|
0
0%
0
|
|
| 109 | M1.OMB.20.4868 | 213840 | Rh Hemolytic Disease of the Newborn |
L2
|
A
|
0
0%
0
|
|
| 110 | M1.ST.20.2 | 213851 | Ulnar nerve |
L2
|
A
|
0
0%
0
|
|
| 111 | M1.OMB.20.1 | 213886 | Anti-Helminth Drugs |
L3
|
A
|
0
0%
0
|
|
| 112 | M1.OMB.20.1 | 213889 | Epithelial Cell Junctions |
L2
|
A
|
0
0%
0
|
|
| 113 | M1.OMB.20.1 | 214259 | Essential Thrombocytosis |
L2
|
A
|
0
0%
0
|
|
| 114 | M1.OMB.20.1 | 214277 | Pure Red Cell Aplasia |
L2
|
A
|
0
0%
0
|
|
| 115 | M1.OMB.20.4695 | 213852 | Portosystemic Anastomoses |
L2
|
A
|
0
0%
0
|
|
| 116 | M1.OMB.20.1 | 213788 | Select Brain Lesions |
L2
|
A
|
0
0%
0
|
|
| 117 | M1.OMB.20.1 | 213778 | Testicular Torsion |
L2
|
A
|
0
0%
0
|
|
| 118 | M1.OMB.20.1 | 213786 | Avascular Necrosis of the Bone (Osteonecrosis) |
L2
|
A
|
0
0%
0
|
|
| 119 | M1.OMB.20.1 | 213715 | Endometrial Hyperplasia |
L3
|
A
|
0
0%
0
|
|
| 120 | M1.OMB.20.1 | 213831 | Thoracic Outlet Syndrome (TOS) |
L2
|
A
|
0
0%
0
|
|
| 121 | M1.PY.17.4698 | 108207 | Personality Disorders |
L3
|
A
|
0
0%
0
|
|
| 122 | M1.BC.17.4695 | 107982 | Fat Soluble Vitamins |
L1
|
A
|
0
0%
0
|
|
| 123 | M1.CV.15.75 | 106831 | Cardiac Cycle |
L1
|
A
|
0
0%
0
|
|
| 124 | M1.NE.17.4697 | 108131 | Aphasia |
L2
|
A
|
0
0%
0
|
|
| 125 | M1.OMB.19.1 | 213406 | Ethical Principles |
L1
|
A
|
0
0%
0
|
|
| 126 | M1.OMB.19.1 | 212698 | Ethical Principles |
L1
|
A
|
0
0%
0
|
|
| 127 | M1.OMB.19.1 | 213578 | Legal Principles |
L2
|
A
|
0
0%
0
|
|
| 128 | M1.OMB.19.1 | 213236 | Legal Principles |
L1
|
A
|
0
0%
0
|
|
| 129 | M1.OMB.19.1 | 213433 | Legal Principles |
L1
|
A
|
0
0%
0
|
|
| 130 | M1.OMB.19.4700 | 213435 | Post-Traumatic Stress Disorder (PTSD) |
L3
|
A
|
0
0%
0
|
|
| 131 | M1.OMB.19.4729 | 212718 | Testing and Screening |
L1
|
A
|
0
0%
0
|
|
| 132 | M1.OMB.19.4800 | 213646 | Lysosome |
L2
|
A
|
0
0%
0
|
|
| 133 | M1.OMB.19.1 | 213600 | Primary Brain Tumors |
L2
|
A
|
0
0%
0
|
|
| 134 | M1.OMB.19.4874 | 213221 | Congestive Heart Failure |
L2
|
A
|
0
0%
0
|
|
| 135 | M1.OMB.19.1 | 212683 | Lipid Lowering Drugs |
L3
|
A
|
0
0%
0
|
|
| 136 | M1.OMB.19.1 | 213708 | Modes of Inheritance |
L2
|
A
|
0
0%
0
|
|
| 137 | M1.OMB.19.4873 | 213183 | Congestive Heart Failure |
L3
|
A
|
0
0%
0
|
|
| 138 | M1.OMB.19.1 | 213775 | Lipid Lowering Drugs |
L3
|
A
|
0
0%
0
|
|
| 139 | M1.OMB.19.1 | 212795 | Antiarrhythmics |
L3
|
A
|
0
0%
0
|
|
| 140 | M1.OMB.19.4799 | 213652 | Antiarrhythmics |
L3
|
A
|
0
0%
0
|
|
| 141 | M1.OMB.19.1 | 212707 | Observational Studies |
L1
|
A
|
0
0%
0
|
|
| 142 | M1.OMB.19.1 | 212877 | Statistical Measures |
L1
|
A
|
0
0%
0
|
|
| 143 | M1.OMB.19.1 | 213584 | Poisons and Treatments |
L3
|
A
|
0
0%
0
|
|
| 144 | M1.OMB.19.1 | 212883 | Nephrotic Syndrome |
L2
|
A
|
0
0%
0
|
|
| 145 | M1.OMB.19.1 | 212868 | Nephrotic Syndrome |
L3
|
A
|
0
0%
0
|
|
| 146 | M1.OMB.19.4755 | 212785 | Lung Cancer |
L2
|
A
|
0
0%
0
|
|
| 147 | M1.OMB.19.1 | 213772 | Lung Cancer |
L2
|
A
|
0
0%
0
|
|
| 148 | M1.OMB.19.1 | 212687 | Myocardial Infarction |
L2
|
A
|
0
0%
0
|
|
| 149 | M1.OMB.19.4874 | 213244 | Water Soluble Vitamins |
L2
|
A
|
0
0%
0
|
|
| 150 | M1.OMB.19.1 | 213429 | Bias |
L1
|
A
|
0
0%
0
|